novo nordisk glp 1 drugs Details of failed studies cast pall on Nordisk's GLP-1 as Alzheimer's treatment FDA asks for removal of
Description
spanning from 2005 to October 2023 utilized the Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate patterns of suicidality associated with GLP-1 RA usage
Alobaid, S
Depression in type 2 diabetes mellitus : prevalence, impact, and treatment
ACS Med Chem Lett
